# Safety board clears LyGenesis ectopic-liver trial to escalate dose after first four patients

Canonical page: https://technooptimist.io/stories/safety-board-clears-lygenesis-ectopic-liver-trial-to-escalate-dose-b9f40901
Date: 4 Mar 2025
About: [LyGenesis](https://technooptimist.io/companies/lygenesis.md) · [LYG-LIV-001 ectopic liver](https://technooptimist.io/longevity/lyg-liv-001.md)
Original source: https://www.biospace.com/press-releases/data-and-safety-monitoring-board-approves-lygenesiss-phase-2a-clinical-trial-to-continue-and-dose-escalate-in-novel-trial-of-organ-regeneration

The trial's Data and Safety Monitoring Board reviewed safety, tolerability and efficacy data from the first cohort of four patients and recommended continuing at a higher dose for the next four. Principal investigator Constance Mobley of Houston Methodist said the team was very encouraged by the therapy's safety and tolerability so far.

## Key facts

- 12 patients planned in cohorts of four; each followed for one year.
- Cells are injected via endoscopic ultrasound into upper abdominal lymph nodes; not genetically engineered.
- Up to half of end-stage liver patients are medically ineligible for transplant; about 12% of wait-listed patients die each year.
- No dose levels or efficacy numbers were released.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.